Table of Contents Author Guidelines Submit a Manuscript
International Journal of Endocrinology
Volume 2017, Article ID 3196059, 8 pages
https://doi.org/10.1155/2017/3196059
Clinical Study

Thickness of Extraocular Muscle and Orbital Fat in MRI Predicts Response to Glucocorticoid Therapy in Graves’ Ophthalmopathy

Department of Endocrinology, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong 510515, China

Correspondence should be addressed to Yaoming Xue; moc.621@999gnimoayeux

Received 3 April 2017; Revised 27 June 2017; Accepted 17 July 2017; Published 6 August 2017

Academic Editor: Jack Wall

Copyright © 2017 Lingling Xu et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. Y. Hiromatsu, H. Eguchi, J. Tani, M. Kasaoka, and Y. Teshima, “Graves’ ophthalmopathy: epidemiology and natural history,” Internal Medicine, vol. 53, no. 5, pp. 353–360, 2014. View at Google Scholar
  2. L. Bartalena, L. Baldeschi, A. J. Dickinson et al., “Consensus statement of the European group on Graves’ orbitopathy (EUGOGO) on management of Graves’ orbitopathy,” Thyroid, vol. 18, no. 3, pp. 333–346, 2008. View at Publisher · View at Google Scholar · View at Scopus
  3. C. Marcocci, L. Bartalena, M. L. Tanda et al., “Comparison of the effectiveness and tolerability of intravenous or oral glucocorticoids associated with orbital radiotherapy in the management of severe Graves’ ophthalmopathy: results of a prospective, single-blind, randomized study,” The Journal of Clinical Endocrinology and Metabolism, vol. 86, no. 8, pp. 3562–3567, 2001. View at Publisher · View at Google Scholar
  4. L. Bartalena, L. Baldeschi, K. Boboridis et al., “The 2016 European Thyroid Association/European Group on Graves’ Orbitopathy Guidelines for the Management of Graves’ Orbitopathy,” European Thyroid Journal, vol. 5, no. 1, pp. 9–26, 2016. View at Publisher · View at Google Scholar · View at Scopus
  5. L. Bartalena, G. E. Krassas, W. Wiersinga et al., “Efficacy and safety of three different cumulative doses of intravenous methylprednisolone for moderate to severe and active Graves’ orbitopathy,” The Journal of Clinical Endocrinology and Metabolism, vol. 97, no. 12, pp. 4454–4463, 2012. View at Publisher · View at Google Scholar · View at Scopus
  6. W. Zhu, L. Ye, L. Shen et al., “A prospective, randomized trial of intravenous glucocorticoids therapy with different protocols for patients with Graves’ ophthalmopathy,” The Journal of Clinical Endocrinology and Metabolism, vol. 99, no. 6, pp. 1999–2007, 2014. View at Publisher · View at Google Scholar · View at Scopus
  7. F. Menconi, M. Leo, E. Sabini et al., “Natural history of Graves’ orbitopathy after treatment,” Endocrine, vol. 5, pp. 1–8, 2016. View at Google Scholar
  8. M. P. Mourits, L. Koornneef, W. M. Wiersinga, M. F. Prummel, A. Berghout, and R. van der Gaag, “Clinical criteria for the assessment of disease activity in Graves’ ophthalmopathy: a novel approach,” The British Journal of Ophthalmology, vol. 73, no. 8, pp. 639–644, 1989. View at Google Scholar
  9. J. Jankauskiene and D. Imbrasiene, “Investigations of ocular changes, extraocular muscle thickness, and eye movements in Graves’ ophthalmopathy,” Medicina, vol. 42, no. 11, pp. 900–903, 2006. View at Google Scholar
  10. E. V. Nagy, J. Toth, I. Kaldi et al., “Graves’ ophthalmopathy: eye muscle involvement in patients with diplopia,” European Journal of Endocrinology, vol. 142, no. 6, pp. 591–597, 2000. View at Google Scholar
  11. N. I. Regensburg, W. M. Wiersinga, T. T. Berendschot, P. Saeed, and M. P. Mourits, “Effect of smoking on orbital fat and muscle volume in Graves’ orbitopathy,” Thyroid, vol. 21, no. 2, pp. 177–181, 2011. View at Publisher · View at Google Scholar · View at Scopus
  12. N. I. Regensburg, W. M. Wiersinga, T. T. Berendschot, P. Potgieser, and M. P. Mourits, “Do subtypes of Graves’ orbitopathy exist?” Ophthalmology, vol. 118, no. 1, pp. 191–196, 2011. View at Publisher · View at Google Scholar · View at Scopus
  13. H. Jiang, Z. Wang, J. Xian, J. Li, Q. Chen, and L. Ai, “Evaluation of rectus extraocular muscles using dynamic contrast-enhanced MR imaging in patients with Graves’ ophthalmopathy for assessment of disease activity,” Acta Radiologica, vol. 53, no. 1, pp. 87–94, 2012. View at Publisher · View at Google Scholar · View at Scopus
  14. R. S. Bahn, “Graves’ ophthalmopathy,” The New England Journal of Medicine, vol. 362, no. 8, pp. 726–738, 2010. View at Publisher · View at Google Scholar · View at Scopus
  15. W. Wiersinga and G. Kahaly, “Graves’ Orbitopathy.” A Multidisciplinary Approach-Questions and Answers, S Karger AG, Switzerland, 2nd revised edition, 2010.
  16. S. Zang, K. A. Ponto, and G. J. Kahaly, “Clinical review: intravenous glucocorticoids for Graves’ orbitopathy: efficacy and morbidity,” The Journal of Clinical Endocrinology and Metabolism, vol. 96, no. 2, pp. 320–332, 2011. View at Publisher · View at Google Scholar · View at Scopus
  17. Y. Nishida, S. Tian, B. Isberg, O. Hayashi, L. Tallstedt, and G. Lennerstrand, “Significance of orbital fatty tissue for exophthalmos in thyroid-associated ophthalmopathy,” Graefe’s Archive for Clinical and Experimental Ophthalmology, vol. 240, no. 7, pp. 515–520, 2002. View at Publisher · View at Google Scholar
  18. I. L. Thornton, J. Clark, J. A. Sokol, M. Hite, and W. R. Nunery, “Radiographic evidence of prominent retro and suborbicularis oculi fat in thyroid-associated orbitopathy,” Orbit, vol. 35, no. 1, pp. 35–38, 2016. View at Publisher · View at Google Scholar · View at Scopus
  19. S. Estcourt, J. Hickey, P. Perros, C. Dayan, and B. Vaidya, “The patient experience of services for thyroid eye disease in the United Kingdom: results of a nationwide survey,” European Journal of Endocrinology, vol. 161, no. 3, pp. 483–487, 2009. View at Publisher · View at Google Scholar · View at Scopus
  20. M. Leo, T. Mautone, I. Ionni et al., “Variables affecting the long-term outcome of Graves’ orbitopathy following high-dose intravenous glucocorticoid pulse therapy in patients not treated with orbital radiotherapy,” Endocrine Practice, vol. 22, no. 10, pp. 1177–1186, 2016. View at Publisher · View at Google Scholar
  21. L. Shen, F. Huang, L. Ye et al., “Circulating microRNA predicts insensitivity to glucocorticoid therapy in Graves’ ophthalmopathy,” Endocrine, vol. 49, no. 2, pp. 445–456, 2015. View at Publisher · View at Google Scholar · View at Scopus
  22. V. M. Naik, M. N. Naik, R. A. Goldberg, T. J. Smith, and R. S. Douglas, “Immunopathogenesis of thyroid eye disease: emerging paradigms,” Survey of Ophthalmology, vol. 55, no. 3, pp. 215–226, 2010. View at Publisher · View at Google Scholar · View at Scopus
  23. K. I. Papageorgiou, C. J. Hwang, S. H. Chang et al., “Thyroid-associated periorbitopathy: eyebrow fat and soft tissue expansion in patients with thyroid-associated orbitopathy,” Archives of Ophthalmology, vol. 130, no. 3, pp. 319–328, 2012. View at Publisher · View at Google Scholar · View at Scopus
  24. D. Imbrasiene, J. Jankauskiene, and D. Stanislovaitiene, “Ultrasonic measurement of ocular rectus muscle thickness in patients with Graves’ ophthalmopathy,” Medicina, vol. 46, no. 7, pp. 472–476, 2010. View at Google Scholar
  25. J. H. Peragallo, F. G. Velez, J. L. Demer, and S. L. Pineles, “Postoperative drift in patients with thyroid ophthalmopathy undergoing unilateral inferior rectus muscle recession,” Strabismus, vol. 21, no. 1, pp. 23–28, 2013. View at Publisher · View at Google Scholar · View at Scopus